Stay updated with breaking news from Preliminary Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...
(PLX AI) - Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses.• Preliminary Phase 2 study and a
Precigen Reports First Quarter 2021 Financial Results - Company on track to achieve stated 2021 milestones - - Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse™ immunotherapy - - Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis (RRP) - - Upcoming presentation at FOCIS Virtual Annual Meeting to provide clinical progress for AG019 ActoBiotics™ in Type 1 diabetes (T1D) - News provided by Share this article Share this article GERMANTOWN, Md., May 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a bioph...
Search jobs 08-Apr-2021 Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update Preliminary Phase 1b Data - Gedatolisib showed a potentially differentiated safety and tolerability profile - Corporate Update - Proceeds from first $15 million tranche increase cash-on-hand to $44 million - - Drug development capabilities and team broadened and expanded - - Conference call and webcast scheduled for today, April 8 at 5 p...
Trial Suggests Russia's COVID-19 Vaccine is 91.6% Effective Feb 02, 2021 10:41 AM 873 views Staff Writer Preliminary Phase 3 trial results from Russia's Sputnik V vaccine shows that it's 91.6% effective against symptomatic Covid-19 and 100% effective against severe and moderate disease. The trial also found that the 2,144 people over the age of 60 tolerated the vaccine well, and the vaccine had a similar efficacy of 91.8%. Out of the total 19,866 participants, 16 cases of symptomatic Covid-19 were confirmed in the vaccine group 21 days after the first vaccine dose. Sixty-two cases were f...